As of November 4, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Lycia Therapeutics, Inc. The largest reported stake is Venrock Healthcare Capital Partners III, L.P.'s, at 11.9%. One filing is on record since October 30, 2026 (Schedule 13G, October 30, 2026).
Sell to companies like Lycia Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Venrock Healthcare Capital Partners III, L.P. · Sole voting: 0 · Shared voting: 6,850,237 · Sole dispositive: 0 · Shared dispositive: 6,850,237 · SCHEDULE 13G, 2026-10-30
- · Reporting person: VHCP Co-Investment Holdings III, LLC · Sole voting: 0 · Shared voting: 6,850,237 · Sole dispositive: 0 · Shared dispositive: 6,850,237 · SCHEDULE 13G, 2026-10-30
- · Reporting person: Venrock Healthcare Capital Partners EG, L.P. · Sole voting: 0 · Shared voting: 6,850,237 · Sole dispositive: 0 · Shared dispositive: 6,850,237 · SCHEDULE 13G, 2026-10-30
- · Reporting person: VHCP Management III, LLC · Sole voting: 0 · Shared voting: 6,850,237 · Sole dispositive: 0 · Shared dispositive: 6,850,237 · SCHEDULE 13G, 2026-10-30
- · Reporting person: VHCP Management EG, LLC · Sole voting: 0 · Shared voting: 6,850,237 · Sole dispositive: 0 · Shared dispositive: 6,850,237 · SCHEDULE 13G, 2026-10-30
Lycia Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2026-10-30. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 11.9% | 6,850,237 | SCHEDULE 13G, 2026-10-30 | 2026-10-23 |
Holding shares or following this stake? See who's behind Lycia Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Lycia Therapeutics, Inc. and the records around it.
Lycia Therapeutics, Inc. elsewhere on the record
- Company profile and every filing Jun 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026), X4 Pharmaceuticals, Inc. (Sep 2026)
Watch Lycia Therapeutics, Inc.
Get an email when Lycia Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lycia Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lycia Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lycia Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| VHCP Co-Investment Holdings III, LLC | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| Venrock Healthcare Capital Partners EG, L.P. | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| VHCP Management III, LLC | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| VHCP Management EG, LLC | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| Venrock Healthcare Capital Partners XP, L.P. | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| VHCP Management XP, LLC | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| Bong Y. Koh | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
| Nimish Shah | 0 | 6,850,237 | 0 | 6,850,237 | SCHEDULE 13G, 2026-10-30 |
The latest filing identifies Lycia Therapeutics, Inc. by CUSIP 55081P100 and gives its principal executive office as 400 East Jamie Court, Suite 200, South San Francisco, CA 94080 (SCHEDULE 13G, 2026-10-30).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.Venrock Healthcare Capital Partners III, L.P., SCHEDULE 13G, 2026-10-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-10-30 | Venrock Healthcare Capital Partners III, L.P. | 11.9% | SCHEDULE 13G |
Also on the record for Lycia Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 23, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| October 20, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| October 5, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| June 25, 2026 | Form D, private offering | $75M sold | Form D page | Source |
Lycia Therapeutics, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Lycia Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.